Admissions:
None.
Delistings:
None.
Switch Metals (SWT.L) (formerly Oneiro Energy ONE.L) announced the completion of the acquisition of Switch Metals Cote d'Ivoire Sarl, a mining exploration company with assets in Cote d'Ivoire, as well as the completion of a £2m fundraise and move from the Main Market to AIM.
Potential** Initial Public Offerings:
17th March: MHA, a professional services provider of audit and assurance, tax, accountancy, and advisory services and independent UK member of Baker Tilly International, announced its Intention to Float on the AIM Market. The Group is seeking to raise up to £125m to provide growth capital for the Company as well as enabling a sell down by certain partners. Alongside the Placing, the Group intends to launch a retail offer to raise up to approximately £6m.
17th March: Quantum Base,the quantum science Company, announced its intention to apply for Admission to trading on the AIM Market during April 2025. Quantum Base is a quantum science company creating a new global standard in authentication through its patented Quantum Identities - near unbreakable and non-replicable authenticity tags that can be applied to a vast array of products, significantly mitigating counterfeiting, and can be authenticated with a smartphone. The Company is seeking to raise between £3m-£5m through a placing, alongside a retail offer.
18th March: Uranium Energy Exploration, to be renamed The Smarter Web Company (AQSE:SWC) is a UK-based web design agency, specialising in creating bespoke, mobile-friendly websites and offers a range of online marketing strategies to help businesses enhance their online presence. Services include various web design packages, logo design, Search Engine Optimisation, animation and custom development. It is looking to do a fundraise of £2m on AQSE. Admission expected 2 April.
4GLOBAL 25p £6.6m (4GBL.L)
The provider of data and technology for sports, fitness and wellness organisations to optimise operational and investment decisions, announced that, following a competitive tender, it has secured a contract renewal and expansion with Sport England worth up to £4m over four years in equal terms.
Sport England initially procured 4GLOBAL in 2021 to provide performance data from public leisure facilities through its platform, Moving Communities, a decision-support tool that uses 4GLOBAL's dataset to aid understanding of where and how people engage in physical activity, enabling a more evidence-based approach to public investment. The platform has since played a central role in programmes such as the National Leisure Recovery Fund and the Swimming Pool Support Fund, tracking over 9 million active people across 1,000+ leisure facilities daily.
Aurrigo International 42.5p £24.6m (AURR.L)
The provider of transport technology solutions announces the launch of Auto-Cargo, its largest autonomous aviation vehicle to date. This marks the latest development following a project initiated in September 2023 in collaboration with UPS. Auto-Cargo is a fully autonomous electric vehicle designed to move heavy cargo loads to and from aircraft, built using a combination of highly engineered hardware and Aurrigo's proprietary autonomous software. The cargo solution offers the potential to transform handling operations by carrying a total payload of 16,500kg when towing a standard trailer, as well as being fully electric and emissions-free versus incumbent diesel vehicles currently in use.
Cambridge Cognition Holdings 36.5p £15.3m (COG.L)
The brain health software group specialising in digital products to advance clinical research and patient treatment has been selected by a major pharmaceutical company to provide digital cognitive and voice assessments for two Phase 3 clinical trials in adolescents with Major Depressive Disorder (MDD). Both contracts are set to commence this year, with the first running until 2027 and the second through to 2029. The total value of the combined contracts is estimated at approximately £1.2m. MDD among adolescents represents a critical public health challenge with significant long-term implications.
Faron Pharmaceuticals OY 199p £222.1m (FARN.L)
The clinical-stage biopharmaceutical Company pursuing a CLEVER-1 receptor targeting approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumors today announces that their lead candidate bexmarilimab has been granted Orphan Drug Designation for the treatment of myelodysplastic syndromes (MDS) by the USA Food and Drug Administration (the FDA). The FDA's Orphan Drug Designation program provides orphan status to drugs defined as those intended for the safe and effective treatment, diagnosis or prevention of rare diseases that affect fewer than 200,000 people in the United States.
Jubilee Metals Group 3.175p £97.3m (JLP.L)
The diversified metals processor in Africa, with copper operations in Zambia and chrome and PGM (Platinum Group Metals) operations in South Africa, announced an update on the Large Waste Project transaction.
Jubilee has secured the exclusive rights to the Large Waste Project for a reduced consideration of US$18m (previously US$30m). The Company has until mid-May 2025 to elect to acquire the assets and settle the approximately US$11.5m remaining of the consideration over a period of 12 months. Jubilee has been performing a due diligence on the Project which included sampling campaigns, laboratory test work and pilot scale trials, the results of which will inform the board's decision as to whether to exercise the option to acquire the assets.
Metals One 15.7p £5.2m (MET1.L)
The Company advancing strategic minerals projects in Finland and Norway announced it has executed a Share Purchase Agreement in respect of the acquisition of the entire issued share capital of FinnAust Mining Finland Oy from 80 Mile Plc (80M.L). As previously announced, the SPV holds certain licences comprising the Hammaslahti Copper-Zinc Project and Outokumpu Copper Project in Finland, which are both associated with former operating copper mines. Following completion and in connection with this Transaction, 80M shall have the right to appoint a director to the Board of Metals One for as long as 80M holds at least 10% of the voting rights of the Company.
MTI Wireless Edge Ltd 51p £44m (MWE.L)
The technology Company focused on comprehensive communication and radio frequency solutions across multiple sectors announced that its subsidiary Mottech Water Solutions has secured a three-year contract extension with one of the largest municipalities in Israel. The contract extension is worth approximately $1.5m over the period.
Nostra Terra Oil and Gas Company 0.021p £1.5m (NTOG.L)
The oil and gas exploration and production Company focused on its Pine Mills producing asset in Texas, USA, announced the following update. Their working interest partner has agreed on a location to drill the Fouke 3 well (32.5% NTOG), with planning ongoing and operational work likely to commence in Q3 2025. Four of the five Pine Mills Phase 2 well workovers are now complete.
Total Company oil production is currently averaging ca.130 bopd net. Production from Pine Mills, currently at 90 bopd net, is expected to increase to between 100 and 135 bopd net on completion in a fortnight following field electrical upgrades.
ValiRx 0.425p £1.6m (VAL.L)
The life science Company focusing on early-stage cancer therapeutics and women's health announces that, further to the announcement on 31 December 2024 to grant a final extension of exclusivity to TheoremRx Inc under the letter of intent (LOI) until 31 May 2025, the Company has terminated the LOI with TheoremRx with immediate effect by mutual agreement. The termination of the LOI follows notification by TheoremRx of a decision not to proceed with an amendment to the LOI to return the territory of Taiwan and maintain exclusivity in exchange for a non-refundable payment of $200,000 by 31 March 2025.
VAL201 will be moved to a prostate cancer focussed special purpose vehicle within ValiRx and plans to file IP to extend the patent life development.
XL Media 10.15p £13.97m (XLM.L)
Following the sale of substantially all the Group's assets in 2024, today’s results for FY December 2024 are presented as discontinued operations. The Company is a cash shell but will not be seeking an RTO. It remains solely focused on the orderly distribution to shareholders of the net proceeds from the Disposals after clearing the Group's liabilities. The cash balances at YE Dec 2024 was $35m and the final payment of consideration of $11.2m was paid by Gambling.com on 1 April 2025. It has returned £14m at 11.5p a share to shareholders on 20th January 2025 by way of a tender offer. The Board proposes to make a further capital return to shareholders prior to the suspension of trading in the Company's shares on or around 12 May 2025 and will make further announcements shortly.
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
